YTHDF1 and colorectal carcinoma: Targeting the METTL3/YTHDF1/LDHA axis significantly enhances CRC cells’ sensitivity to 5‐FU in both in vivo and in vitro settings, presenting a potential therapeutic target to overcome 5‐FU resistance.217